4 completed, 2 active not recruiting, 2 terminated, 1 recruiting. 7 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Terminated 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Ponatinib Hydrochloride: new trials by email Literature Review of Ponatinib Hydrochloride trials Research Report on Ponatinib Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 348 | 2021-01-25 | 2026-10-26 |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Dexamethasone, Ponatinib Hydrochloride, Rituximab - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2018-06-26 | 2025-05-08 |
| Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dasatinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | OHSU Knight Cancer Institute | 7 | 2016-01-13 | 2020-05-26 |
| Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma Ponatinib - Glioblastoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 17 | 2015-07-13 | 2018-07-24 |
| Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. ponatinib hydrochloride, laboratory biomarker analysis - Malignant Neoplasm | Phase 2 | Completed | Sameek Roychowdhury | 22 | 2015-02-24 | 2025-03-24 |
| Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions Laboratory Biomarker Analysis, Ponatinib Hydrochloride, Quality-of-Life Assessment - Malignant Hepatobiliary Neoplasm | Phase 2 | Completed | Mayo Clinic | 12 | 2014-12-01 | 2020-11-25 |
| Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib Laboratory Biomarker Analysis, Ponatinib Hydrochloride, Quality-of-Life Assessment - Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2013-01-17 | 2026-09-16 |
| Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Antitumor Drug Screening Assay, Dasatinib, Idelalisib - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Terminated | OHSU Knight Cancer Institute | 12 | 2012-05-11 | 2021-11-04 |
| Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dexamethasone - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 88 | 2011-10-05 | 2026-10-06 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Blast Crisis (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Acute (2) · Glioblastoma (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Chronic-Phase (1) · Leukemia, Myelomonocytic, Chronic (1) · Neoplasms (1) · Piebaldism (1)
M.D. Anderson Cancer Center (3) · OHSU Knight Cancer Institute (2) · Dana-Farber Cancer Institute (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Sameek Roychowdhury (1)
United States (9) · Israel (1) · Puerto Rico (1)
Elias Jabbour (1) · Elias Jabbour, MD (1) · Eudocia Lee, MD (1) · Farhad Ravandi-Kashani (1) · Marc Loriaux (1) · Mitesh Borad (1) · Sameek Roychowdhury, MD, PhD (1) · Stephen Spurgeon (1) · Yishai Ofran (1)
PMID 25763789, PMID 26432046, PMID 30501869, PMID 36600670, PMID 41671463
P30CA015083 (1), P30CA069533 (1), R21CA159265 (1), U10CA180820 (1)